知镜 Cognispect · 医学文献与研究工作台

Dapagliflozin modulates diabetic kidney disease through indirect transcriptional regulation rather than direct transcriptional reversal.

Pesce F, Strizzi CT, Granata A, Bracaccia ME, Muzi L, Liakopoulos V, Grandaliano G.
Journal of nephrology · 2026-08-01 · PMID 42489012

文献摘要

Background Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) confer remarkable renoprotection, the molecular mechanisms underlying their efficacy remain incompletely understood. Methods We performed an integrative cross-species transcriptomic analysis comparing dapagliflozin-modulated signatures in diabetic mice with human DKD pathophysiology. Public RNA-sequencing datasets were analyzed: GSE142025 (human kidney biopsies: advanced DKD n = 21, early DKD n = 6, controls n = 9) and GSE228727 (diabetic db/db mice ± dapagliflozin). Results Advanced human DKD exhibited 2145 dysregulated genes (False Discovery Rate [FDR] Conclusion SGLT2 inhibitors do not reverse disease transcriptional programs but operate through indirect modulation of a focused gene signature largely independent of primary disease drivers. This signature provides prioritized candidates for mechanistic investigation and biomarker development in DKD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。